China’s CARsgen Therapeutics has announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma 12 October 2023
Despite positive topline data, Syndax Pharmaceuticals stock has fallen more than a tenth, following an interim analysis from the AUGMENT-101 trial. 3 October 2023
Gilead Sciences has released a statement confirming it has stopped its ENHANCE-2 study of magrolimab in acute myeloid leukemia (AML). 27 September 2023
The European Commission (EC) has granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy to treat adults with relapsed or refrac 25 September 2023
The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) alongside lenalidomide and dexamethasone (DLd) for untreated 22 September 2023
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer an 20 September 2023
Swiss pharma firm Acino has acquired M8 Pharmaceuticals, a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and 20 September 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.